C-peptide and diabetic neuropathy.

Area of Science:

• Endocrinology
• Neurology
• Diabetology

Background:

• Diabetic polyneuropathy (DPN) is a common complication of diabetes, disproportionately affecting Type 1 diabetes patients.
• Metabolic, molecular, and structural mechanisms of DPN differ between Type 1 and Type 2 diabetes.
• Impaired insulin/C-peptide action is a key factor in Type 1 diabetes pathogenesis.

Purpose of the Study:

• To investigate the therapeutic potential of C-peptide in mitigating Type 1 diabetic polyneuropathy.
• To review preclinical and clinical evidence supporting C-peptide's neuroprotective effects.

Main Methods:

• Review of preclinical studies on C-peptide's molecular and cellular effects in Type 1 diabetes models.
• Analysis of small-scale clinical trials assessing C-peptide's impact on nerve function and blood flow.

Main Results:

• Preclinical studies demonstrate C-peptide's positive effects on Na(+)/K(+)-ATPase, nitric oxide synthase, neurotrophic factors, and apoptosis.
• Animal studies show C-peptide promotes nerve regeneration, protects against structural damage, and improves functional deficits.
• Clinical trials indicate beneficial effects of C-peptide on autonomic and somatic nerve function and tissue blood flow.

Conclusions:

• C-peptide exhibits insulin-like effects without altering blood glucose levels, suggesting a distinct therapeutic role.
• Evidence supports C-peptide replacement therapy for retarding and preventing chronic complications in Type 1 diabetes.
• Large-scale clinical trials are warranted to further validate C-peptide's efficacy and facilitate its clinical use.